These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory
held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs;
safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay
dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
(updated 2/1/2018) Lesson 2:
Dividend Growth (updated 2/8/2018) Lesson 3: The 5 - Year Rule (updated 3/12/2018) Lesson 4: The Power
of Compounding (updated 3/20/2018) Lesson 5: The Power
of Reinvesting
Dividends (updated 4/12/208) Lesson 6: Yield and Yield on Cost (updated 4/26/2018) Lesson 7:
Dividends are Independent from the Market Lesson 8: How to Collect 10 % Yields from Great
Dividend Growth Stocks Lesson 9: Why I've Loaded My Portfolio with
Dividend Growth Stocks Lesson 10 (Part I): Reinvest Your
Dividends Selectively to Enhance Your Returns Lesson 10 (Part II): Reinvest Your
Dividends Automatically to Build Long - Term Positions Lesson 11: Valuation Lesson 12 (Part I): Invest According to a Plan Lesson 12 (Part II): Invest According to a Plan Lesson 13: Specific Suggestions for YOUR
Dividend Growth Investing Plan Lesson 14: Buying Lesson 15:
Holding and Selling Lesson 16: Diversification Lesson 17:
Dividend Safety Lesson 18: High Yield or Fast Growth?